

Invega Sustenna® Review

1. You are preparing to administer Invega Sustenna® to a patient who weighs 146 pounds. What size needle will you use?

1 inch needle/23 gauge for patients weighing less than 90 kg, pt 146lb/2.2lb = 66.4 kg, needle included in the package (blue for this patient) _____

2. Name the most common side effects a patient may experience when taking Invega Sustenna®.

The most common side effects/adverse effects were injection site reactions, somnolence/sedation, dizziness, akathisia, and extrapyramidal disorder.

3. What black box warning is associated with this medication?

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. INVEGA SUSTENA is not approved for use in patients with dementia-related psychosis.

4. What are the standard *recommended* Day 1 and Day 8 initiation dosages for a person with schizophrenia?

Day 1 = 234mg, Day 8 = 156mg

5. What is the standard *recommended* maintenance dosage for a patient with schizophrenia?

Monthly maintenance dose is 39-234mg (Max dose 234 mg monthly)

6. What is the correct location for administration of the Day 1 and Day 8 initiation doses?

Deep, slow gluteal or deltoid intramuscular injection

7. What are the *recommended* Day 1 and Day 8 initiation dosages for a person with a creatinine clearance of 65mL/min?

For patients with mild renal impairment (Cr clearance greater than or equal to 50 ml/min to < 80 ml/min) initiate INVEGA SUSTENA with a dose of 156 mg on treatment day 1, 117mg on Day 8, both in the deltoid muscle.

8. What would the *recommended* maintenance dosage be for a patient with mild renal impairment?

Follow with the recommended maintenance monthly dose of 78mg, administered in either the deltoid or gluteal muscle. Adjust monthly maintenance dose based on tolerability and/or efficacy within the strengths of 39mg, 78mg, 117mg or 156 mg. Max dose monthly for patients with mild renal impairment is 156 mg.

9. What is the rationale for a trial of oral paliperidone or oral or injectable risperidone before placing a patient on Invega Sustenna®?

The rationale for a trial of oral paliperidone or oral or injectable risperidone is to establish tolerability prior to initiation of Invega Sustenna.

10. Name three practices when preparing an intramuscular injection that ensure aseptic technique is maintained throughout the procedure.
The following aseptic technique for administration must be maintained for safety of patient and staff.

1. Hand Hygiene prior to donning gloves
2. Alcohol swab the injection site after determining location of injection projection, allowing site to fully dry of alcohol after cleaning site.
3. Slow deep injection at cleaned site, and covering penetration of the needle to skin to ensure barrier protection from invasion of pathogen.

11. Explain the rationale for obtaining consent for this psychoactive medication prior to preparing the medication for administration.

The rationale for obtaining consent for this psychoactive medication prior to preparing this medication for administration is to fully inform the patient of understanding the rights of the patient. The medication dosage, route, expected outcomes of administration and efficacy, the adverse effects possible after administration are all included in the consent. This informed consent also reminds the patient who is authorizing this medication and the right to decline the medication at any time they should feel the necessity to stop said treatment therapy.